These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

246 related articles for article (PubMed ID: 24901804)

  • 1. Antithrombin concentrate in pediatric patients requiring unfractionated heparin anticoagulation: a retrospective cohort study.
    Ryerson LM; Bauman ME; Kuhle S; Bruce AA; Massicotte MP
    Pediatr Crit Care Med; 2014 Oct; 15(8):e340-6. PubMed ID: 24901804
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Antithrombin Concentrate Use in Children Receiving Unfractionated Heparin for Acute Thrombosis.
    Diaz R; Moffett BS; Karabinas S; Guffrey D; Mahoney DH; Yee DL
    J Pediatr; 2015 Sep; 167(3):645-9. PubMed ID: 26148660
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Anti-factor Xa assay is a superior correlate of heparin dose than activated partial thromboplastin time or activated clotting time in pediatric extracorporeal membrane oxygenation*.
    Liveris A; Bello RA; Friedmann P; Duffy MA; Manwani D; Killinger JS; Rodriquez D; Weinstein S
    Pediatr Crit Care Med; 2014 Feb; 15(2):e72-9. PubMed ID: 24335992
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The influence of free hemoglobin and bilirubin on heparin monitoring by activated partial thromboplastin time and anti-Xa assay.
    Kostousov V; Nguyen K; Hundalani SG; Teruya J
    Arch Pathol Lab Med; 2014 Nov; 138(11):1503-6. PubMed ID: 25357112
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evaluation of weight-based dosing of unfractionated heparin in obese children.
    Taylor BN; Bork SJ; Kim S; Moffett BS; Yee DL
    J Pediatr; 2013 Jul; 163(1):150-3. PubMed ID: 23414664
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Activated partial thromboplastin time versus antifactor Xa heparin assay in monitoring unfractionated heparin by continuous intravenous infusion.
    Guervil DJ; Rosenberg AF; Winterstein AG; Harris NS; Johns TE; Zumberg MS
    Ann Pharmacother; 2011 Jul; 45(7-8):861-8. PubMed ID: 21712506
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparing Anti-Factor Xa and Activated Partial Thromboplastin Levels for Monitoring Unfractionated Heparin.
    Wahking RA; Hargreaves RH; Lockwood SM; Haskell SK; Davis KW
    Ann Pharmacother; 2019 Aug; 53(8):801-805. PubMed ID: 30813751
    [No Abstract]   [Full Text] [Related]  

  • 8. In vivo age dependency of unfractionated heparin in infants and children.
    Newall F; Ignjatovic V; Summerhayes R; Gan A; Butt W; Johnston L; Monagle P
    Thromb Res; 2009 Mar; 123(5):710-4. PubMed ID: 18829072
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Higher doses of low-molecular-weight heparin (enoxaparin) are needed to achieve target anti-Xa concentrations in critically ill children*.
    Schloemer NJ; Abu-Sultaneh S; Hanson SJ; Yan K; Hoffmann RG; Punzalan RC; Havens PL
    Pediatr Crit Care Med; 2014 Sep; 15(7):e294-9. PubMed ID: 24901803
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Challenges with heparin-based anticoagulation during cardiopulmonary bypass in children: Impact of low antithrombin activity.
    Manlhiot C; Gruenwald CE; Holtby HM; Brandão LR; Chan AK; Van Arsdell GS; McCrindle BW
    J Thorac Cardiovasc Surg; 2016 Feb; 151(2):444-50. PubMed ID: 26553458
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Administration of antithrombin concentrate in infants and children on extracorporeal life support improves anticoagulation efficacy.
    Ryerson LM; Bruce AK; Lequier L; Kuhle S; Massicotte MP; Bauman ME
    ASAIO J; 2014; 60(5):559-63. PubMed ID: 24814836
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Antithrombin concentrates use in children on extracorporeal membrane oxygenation: a retrospective cohort study.
    Wong TE; Delaney M; Gernsheimer T; Matthews DC; Brogan TV; Mazor R; McMullan DM; Reiner AP; Konkle BA
    Pediatr Crit Care Med; 2015 Mar; 16(3):264-9. PubMed ID: 25581634
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effectiveness of a Calculation-Free Weight-Based Unfractionated Heparin Nomogram With Anti-Xa Level Monitoring Compared With Activated Partial Thromboplastin Time.
    Kindelin NM; Anthes AM; Providence SM; Zhao X; Aspinall SL
    Ann Pharmacother; 2021 May; 55(5):575-583. PubMed ID: 32964730
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A Randomized Controlled Trial of Antithrombin Supplementation During Extracorporeal Membrane Oxygenation.
    Panigada M; Cucino A; Spinelli E; Occhipinti G; Panarello G; Novembrino C; Consonni D; Protti A; Lissoni A; Arcadipane A; Pesenti A; Grasselli G
    Crit Care Med; 2020 Nov; 48(11):1636-1644. PubMed ID: 32947474
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Discordant aPTT and anti-Xa values and outcomes in hospitalized patients treated with intravenous unfractionated heparin.
    Price EA; Jin J; Nguyen HM; Krishnan G; Bowen R; Zehnder JL
    Ann Pharmacother; 2013 Feb; 47(2):151-8. PubMed ID: 23386070
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Thrombin formation and effect of unfractionated heparin during pediatric cardiac catheterization.
    Chen D; Långström S; Petäjä J; Heikinheimo M; Pihkala J
    Catheter Cardiovasc Interv; 2013 Jun; 81(7):1174-9. PubMed ID: 22915548
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Supplemental Antithrombin Is Effective in Achieving Adequate Anticoagulation in Infants and Children With an Inadequate Response to Heparin.
    Lopez M; Feng C; Vasilyeva O; Eaton MP
    J Cardiothorac Vasc Anesth; 2017 Jun; 31(3):896-900. PubMed ID: 28242144
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Anti-Factor Xa-Based Monitoring of Unfractionated Heparin: Clinical Outcomes in a Pediatric Cohort.
    Saini S; Folta AN; Harsh KL; Stanek JR; Dunn AL; O'Brien SH; Kumar R
    J Pediatr; 2019 Jun; 209():212-219.e1. PubMed ID: 30961988
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of anti-Xa and activated partial thromboplastin time monitoring for heparin dosing in patients with cirrhosis.
    Fuentes A; Gordon-Burroughs S; Hall JB; Putney DR; Monsour HP
    Ther Drug Monit; 2015 Feb; 37(1):40-4. PubMed ID: 24901494
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Anticoagulation monitoring during pediatric extracorporeal membrane oxygenation.
    Bembea MM; Schwartz JM; Shah N; Colantuoni E; Lehmann CU; Kickler T; Pronovost P; Strouse JJ
    ASAIO J; 2013; 59(1):63-8. PubMed ID: 23263338
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.